Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
AASLD, Arbitration, Asia, authoritative, beneficiary, biodistribution, boceprevir, Bradmer, budgetary, burden, carboplatin, classification, coordination, curtail, curtailed, dampen, derecognition, diplomatic, disruption, doubled, DTRA, duration, Eastern, endpoint, enrichment, Europe, excellent, explanatory, FDAMA, foundation, fourteen, gathered, geopolitical, Georgia, indirect, injunctive, intentionally, irradiated, letter, literature, lost, MD, Medibiotech, Merk, Modernization, monetary, MTA, Neuradiab, notified, notifying, NSCLC, paragraph, phospholipid, political, posturing, prone, prophylactic, rational, recurring, refunded, Renshaw, reverse, Rodman, serial, sheet, shortly, simultaneously, Social, sparing, sponsorship, stem, sublicensee, surrogate, taxable, Threat, TMTI, Transformational, underway, unjust, unmet, update, worth
Removed:
aberrant, account, alter, assisting, calculate, clot, consultant, Darmstadt, deliver, directed, expand, family, favorable, flow, funded, inhibiting, insufficient, interfere, leaky, leveraging, localized, member, permeable, pertaining, physiology, ranged, selectively, SPE, vasoactive, vessel
Filing tables
Filing exhibits
CDMO similar filings
Filing view
External links
EXHIBIT 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-130271, 333-121334, 333-106385, 333-57046, and 333-17513; Form S-3 Nos. 333-139975, 333-132872, 333-128322, 333-121450, 333-109982, 333-103965, 333-99157, 333-71086, and 333-40716) of Peregrine Pharmaceuticals, Inc. of our reports dated July 10, 2008, with respect to the consolidated financial statements and schedule of Peregrine Pharmaceuticals, Inc., and the effectiveness of internal control over financial reporting of Peregrine Pharmaceuticals, Inc., included in the Annual Report (Form 10-K) for the year ended April 30, 2008.
/s/ Ernst & Young LLP | |
Orange County, California July 10, 2008 |